The University of Chicago Header Logo

Connection

Hannah Ryles to Drug Resistance, Neoplasm

Back to Details
This is a "connection" page, showing publications Hannah Ryles has written about Drug Resistance, Neoplasm.
Hannah Ryles
Connection Strength
0.116
Drug Resistance, Neoplasm
  1. The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma. Cancer Discov. 2016 Jan; 6(1):96-107.
    View in: PubMed
    Score: 0.094
  2. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell. 2014 Nov 10; 26(5):682-94.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.